Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 170

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression

Open access
Horiuchi, Dai, Camarda, Roman, Zhou, Alicia Y, Yau, Christina, Momcilovic, Olga, Balakrishnan, Sanjeev, Corella, Alexandra N, Eyob, Henok, Kessenbrock, Kai, Lawson, Devon A, Marsh, Lindsey A, Anderton, Brittany N, Rohrberg, Julia, Kunder, Ratika, Bazarov, Alexey V, Yaswen, Paul, McManus, Michael T, Rugo, Hope S, Werb, Zena, Goga, Andrei·2016·Nature Medicine

Abstract

Triple-negative breast cancer (TNBC), in which cells lack expression of the estrogen receptor (ER), the progesterone receptor (PR) and the ERBB2 (also known as HER2) receptor, is the breast cancer subtype with the poorest outcome. No targeted therapy is available against this subtype of cancer owing to a lack of validated molecular targets. We previously reported that signaling involving MYC—an essential, pleiotropic transcription factor that regulates the expression of hundreds of genes—is disproportionally higher in triple-negative (TN) tumors than in receptor-positive (RP) tumors. Direct inhibition of the oncogenic transcriptional activity of MYC has been challenging to achieve. Here, by conducting a shRNA screen targeting the kinome, we identified PIM1, a non-essential serine–threonine kinase, in a synthetic lethal interaction with MYC. PIM1 expression was higher in TN tumors than in RP tumors and was associated with poor prognosis in patients with hormone- and HER2-negative tumors. Small-molecule PIM kinase inhibitors halted the growth of human TN tumors with elevated MYC expression in patient-derived tumor xenograft (PDX) and MYC-driven transgenic mouse models of breast cancer by inhibiting the oncogenic transcriptional activity of MYC and restoring the function of the endogenous cell cycle inhibitor, p27. Our findings warrant clinical evaluation of PIM kinase inhibitors in patients with TN tumors that have elevated MYC expression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm.4213

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 170

Metadata

Authors
Horiuchi, D., Camarda, R., Zhou, A. Y., Yau, C., Momcilovic, O., Balakrishnan, S., Corella, A. N., Eyob, H., Kessenbrock, K., Lawson, D. A., Marsh, L. A., Anderton, B. N., Rohrberg, J., Kunder, R., Bazarov, A. V., Yaswen, P., McManus, M. T., Rugo, H. S., Werb, Z., & Goga, A.
Venue
Nature Medicine
Published
2016-10-24
Volume
22
Issue
11
Pages
1321-1329
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2534173999
Cited by
170
References
9
FWCI
8.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. https://app.cochat.ai/papers/10.1038/nm.4213
The paper
Horiuchi, D., Camarda, R., Zhou, A. Y., Yau, C., Momcilovic, O., Balakrishnan, S., Corella, A. N., Eyob, H., Kessenbrock, K., Lawson, D. A., Marsh, L. A., Anderton, B. N., Rohrberg, J., Kunder, R., Bazarov, A. V., Yaswen, P., McManus, M. T., Rugo, H. S., Werb, Z., & Goga, A. (2016). PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nature Medicine. https://doi.org/10.1038/nm.4213

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.